Phytochemicals for the Management of Melanoma

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2016 Feb 12

PMID 26864554

Citations 28

Authors

Harish Chandra Pal

Katherine Marchiony Hunt

Ariana Diamond

Craig A Elmets

Farrukh Afaq

Affiliations

Soon will be listed here.

Abstract

Melanoma claims approximately 80% of skin cancer-related deaths. Its life-threatening nature is primarily due to a propensity to metastasize. The prognosis for melanoma patients with distal metastasis is bleak, with median survival of six months even with the latest available treatments. The most commonly mutated oncogenes in melanoma are BRAF and NRAS accounting approximately 60% and 20% of cases, respectively. In malignant melanoma, accumulating evidence suggests that multiple signaling pathways are constitutively activated and play an important role in cell proliferation, cell survival, epithelial to mesenchymal transition, metastasis and resistance to therapeutic regimens. Phytochemicals are gaining considerable attention because of their low toxicity, low cost, and public acceptance as dietary supplements. Cell culture and animals studies have elucidated several cellular and molecular mechanisms by which phytochemicals act in the prevention and treatment of metastatic melanoma. Several promising phytochemicals, such as, fisetin, epigallocatechin-3-gallate, resveratrol, curcumin, proanthocyanidins, silymarin, apigenin, capsaicin, genistein, indole-3-carbinol, and luteolin are gaining considerable attention and found in a variety of fresh fruits, vegetables, roots, and herbs. In this review, we will discuss the preventive potential, therapeutic effects, bioavailability and structure activity relationship of these selected phytochemicals for the management of melanoma.

Citing Articles

Predictive Production of a New Highly Soluble Glucoside, Corylin-7-O-β-Glucoside with Potent Anti-inflammatory and Anti-melanoma Activities.

Chang T, Wu J, Ding H, Tayo L, Suratos K, Tsai P Appl Biochem Biotechnol. 2024; 197(2):1174-1191.

PMID: 39377873 DOI: 10.1007/s12010-024-05071-6.

Recent Updates Regarding the Antiproliferative Activity of Extracts on A375 Human Malignant Melanoma Cell Line.

Semenescu A, Moaca E, Iftode A, Dehelean C, Tchiakpe-Antal D, Vlase L Life (Basel). 2024; 14(1).

PMID: 38255727 PMC: 10820234. DOI: 10.3390/life14010112.

Silver Nanoparticles Synthesized from and Bark Extracts: Characterization, Antioxidant, Cytotoxic, and Antibacterial Effects.

Macovei I, Luca S, Skalicka-Wozniak K, Horhogea C, Rimbu C, Sacarescu L Antioxidants (Basel). 2023; 12(4).

PMID: 37107172 PMC: 10135277. DOI: 10.3390/antiox12040797.

Redox Properties, Bioactivity and Health Effects of Indicaxanthin, a Bioavailable Phytochemical from , L.: A Critical Review of Accumulated Evidence and Perspectives.

Attanzio A, Restivo I, Tutone M, Tesoriere L, Allegra M, Livrea M Antioxidants (Basel). 2022; 11(12).

PMID: 36552572 PMC: 9774763. DOI: 10.3390/antiox11122364.

Drug Delivery Systems and Flavonoids: Current Knowledge in Melanoma Treatment and Future Perspectives.

Cunha C, Daniel-da-Silva A, Oliveira H Micromachines (Basel). 2022; 13(11).

PMID: 36363859 PMC: 9693869. DOI: 10.3390/mi13111838.

References

Bohm M, Schulte U, Funk J, Raghunath M, Behrmann I, Kortylewski M . Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol. 2001; 117(1):132-40. DOI: 10.1046/j.0022-202x.2001.01372.x. View

Briggs J . Histological diagnosis and prognosis of malignant melanoma. J Clin Pathol. 1980; 33(7):702. PMC: 1146194. DOI: 10.1136/jcp.33.7.702-b. View

Ravindranath M, Ramasamy V, Moon S, Ruiz C, Muthugounder S . Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG). Evid Based Complement Alternat Med. 2008; 6(4):523-30. PMC: 2781776. DOI: 10.1093/ecam/nem140. View

Walpole C, Wrigglesworth R, Bevan S, Campbell E, Dray A, James I . Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region". J Med Chem. 1993; 36(16):2381-9. DOI: 10.1021/jm00068a016. View

Afaq F, Katiyar S . Polyphenols: skin photoprotection and inhibition of photocarcinogenesis. Mini Rev Med Chem. 2011; 11(14):1200-15. PMC: 3288507. DOI: 10.2174/13895575111091200. View

Sharma R, Gescher A, Steward W . Curcumin: the story so far. Eur J Cancer. 2005; 41(13):1955-68. DOI: 10.1016/j.ejca.2005.05.009. View

Zheng X, Yu L, Yang J, Yao X, Yan W, Bo S . Synthesis and anti-cancer activities of apigenin derivatives. Med Chem. 2014; 10(7):747-52. DOI: 10.2174/1573406410666140307152557. View

Lu M, Miller P, Lu X . Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett. 2014; 588(16):2616-21. DOI: 10.1016/j.febslet.2014.05.008. View

Li L, Wu L, Jiang Y, Tashiro S, Onodera S, Uchiumi F . Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells. J Asian Nat Prod Res. 2007; 9(6-8):593-602. DOI: 10.1080/10286020600882502. View

10.

Yan C, Han R . Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis. 1997; 17(4):189-98. View

11.

Patel D, Shukla S, Gupta S . Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol. 2006; 30(1):233-45. View

12.

Seguin J, Brulle L, Boyer R, Lu Y, Ramos Romano M, Touil Y . Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm. 2013; 444(1-2):146-54. DOI: 10.1016/j.ijpharm.2013.01.050. View

13.

Jochemsen A . Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin Oncol. 2013; 26(1):114-9. DOI: 10.1097/CCO.0000000000000033. View

14.

Thomas K, Ethirajan M, Shahrokh K, Sun H, Lee J, Cheatham 3rd T . Structure-activity relationship of capsaicin analogs and transient receptor potential vanilloid 1-mediated human lung epithelial cell toxicity. J Pharmacol Exp Ther. 2011; 337(2):400-10. PMC: 3083109. DOI: 10.1124/jpet.110.178491. View

15.

Chintharlapalli S, Papineni S, Baek S, Liu S, Safe S . 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal.... Mol Pharmacol. 2005; 68(6):1782-92. DOI: 10.1124/mol.105.017046. View

16.

Appendino G, Harrison S, De Petrocellis L, Daddario N, Bianchi F, Moriello A . Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br J Pharmacol. 2003; 139(8):1417-24. PMC: 1573981. DOI: 10.1038/sj.bjp.0705387. View

17.

Philip S, Kundu G . Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2002; 278(16):14487-97. DOI: 10.1074/jbc.M207309200. View

18.

McGOVERN V . The nature of melanoma. A critical review. J Cutan Pathol. 1982; 9(2):61-81. DOI: 10.1111/j.1600-0560.1982.tb01044.x. View

19.

Hocker T, Tsao H . Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat. 2007; 28(6):578-88. DOI: 10.1002/humu.20481. View

20.

Dodo K, Minato T, Hashimoto Y . Structure-activity relationship of bis-galloyl derivatives related to (-)-epigallocatechin gallate. Chem Pharm Bull (Tokyo). 2009; 57(2):190-4. DOI: 10.1248/cpb.57.190. View